Until recently, a few studies directly indicate that blocking COX2/PGE2 signaling has a profound effect on dysfunctional CTLs in patients going through immunotherapy for viral infection or cancer, indirect evidence suggests that therapies through inhibition of COX-2/PGE2 signaling may enhance CTLs function. The gene discussed is PTGS2; the disease is cancer.